A Phase 1B Study of E7386 and Lenvatinib in People With Advanced Endometrial Cancer


Full Title

An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors


Researchers want to find the best doses of E7386 and lenvatinib to use in people with endometrial cancer. The people in this study have endometrial cancer that keeps growing even after treatment.

E7386 blocks signals between proteins that help cancer cells grow and survive. Lenvatinib blocks proteins called tyrosine kinases, which help cells grow and develop new blood vessels. Blocking these proteins may slow the growth of cancer cells and cut off the blood supply that feeds them. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have endometrial cancer that keeps growing or came back even after treatment.
  • Have recovered from the serious side effects of previous therapies.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Chrisann Kyi’s office at 646-888-4221.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID